Home / 2015 / January (page 2)

Monthly Archives: January 2015

Compugen Discloses Initial Experimental Results for Predicted Antibody Drug Conjugate Targets קומפיוג’ן: תוצאות ניסוייות חיוביות עבור 2 מ-5 חלבוני מטרה פוטנציאליים

Compugen, a drug discovery company that uses computational biology to predict and select product candidates, announced positive initial experimental results for the first two of five in silico-predicted targets for antibody drug conjugate (ADC) cancer therapy disclosed in late 2013. ...

Read More »

RedHill Biopharma Business Outlook and Anticipated Key Milestones for 2015 התחזית העסקית ואבני הדרך הצפוי של רדהיל ביופרמה ב2015

RedHill BioPharma Ltd., a biopharmaceutical company focused on the development and acquisition of late clinical-stage orally administered drugs for treating inflammatory and gastrointestinal diseases, announced selected key milestones and events anticipated in 2015. Upcoming milestones include: Top-line data from ongoing first Phase III study ...

Read More »

BrainStorm Announces Final Analysis of Phase 2a ALS Study Showing Nearly All Subjects Experienced Clinical Benefit from NurOwn™ בריינסטורם מכריז על מחקר שהראה שנור-און מועיל קלינית לכמעט כל החולים

BrainStorm Cell Therapeutics Inc. announced positive results in its Phase IIa clinical trial of its NurOwn stem cell therapy technology for amyotrophic lateral sclerosis (ALS). 92% of the 14 subjects enrolled at Hadassah Medical Center experienced an improvement in the rate of ALS ...

Read More »

Protalix BioTherapeutics Announces New Strategy for Accelerated Growth פרוטליקס מכריז על אסטרטגיה חדשה לצמיחה מואצת

Protalix Biotherapeutics, a biopharmaceutical company focused on developing recombinant therapeutic proteins expressed through its plant cell-based expression system, is prioritizing pipeline candidates to focus on bio-better products with a clear competitive advantage. Therapeutic areas of focus will include Fabry disease, inflammatory bowel disease, ...

Read More »

NeuroDerm Share Prices Soar After Positive Results in Phase IIa Parkinson’s Trial המניה של נוירודרם הוכפל לאור תוצאות ניסוי לטיפול בפרקינסון

Rehovot-based NeuroDerm Ltd. (NASDAQ: NDRM) ended 2014 on a high note as it saw its share price more than double following announcement of positive results in a Phase IIa Parkinson’s drug trial. According to the company, administration of a continuous subcutaneous high-level dose of ...

Read More »

Enzymotec Ltd. Announces an Extraordinary General Meeting of Shareholders אנזימוטק בע"מ מכריז על אסיפה כללית מיוחדת של בעלי מניות

Enzymotec Ltd., an Israel-based global company that modifies lipids harvested from natural sources to develop nutritional ingredients and medical foods, will hold an Extraordinary General Meeting of Shareholders in February. The purpose of the meeting is to elect a director, approve ...

Read More »